Phase I dose-escalation study evaluating safety,tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody,in Japanese patients with advanced solid tumours |
| |
| Authors: | Haruo Iguchi Tomohiro Nishina Naoyuki Nogami Toshiyuki Kozuki Yumiko Yamagiwa Katsuro Yagawa |
| |
| Affiliation: | 1. Clinical Research Center, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-chou, Matsuyama City, Ehime Prefecture, 791-0280, Japan
2. AstraZeneca, Osaka, Japan
|
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
